{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T12:02:22Z","timestamp":1770897742179,"version":"3.50.1"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Chungnam National University, Institute of Information & communications Technology Planning Evaluation","award":["No.RS-2022-00155857"],"award-info":[{"award-number":["No.RS-2022-00155857"]}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["RS-2023-00278597"],"award-info":[{"award-number":["RS-2023-00278597"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF-2022R1A2C1010929"],"award-info":[{"award-number":["NRF-2022R1A2C1010929"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["NRF2022R1A5A7085156"],"award-info":[{"award-number":["NRF2022R1A5A7085156"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003654","name":"Korea Environmental Industry Technology Institute","doi-asserted-by":"crossref","award":["2021003310001"],"award-info":[{"award-number":["2021003310001"]}],"id":[{"id":"10.13039\/501100003654","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s13318-024-00917-0","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T01:01:21Z","timestamp":1727053281000},"page":"701-714","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic and Pharmacodynamic Interaction of Finerenone with Diltiazem, Fluconazole, and Ritonavir in Rats"],"prefix":"10.1007","volume":"49","author":[{"given":"Tham Thi","family":"Bui","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So-Hyeon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Woojin","family":"Jung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sung-yoon","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quyen Thi","family":"Tran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyunjung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seongwon","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lien Thi","family":"Ngo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hwi-yeol","family":"Yun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6026-7063","authenticated-orcid":false,"given":"Jung-woo","family":"CHAE","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"917_CR1","unstructured":"U.S. Centers for Disease Control and Prevention (CDC). Diabetes and Chronic Kidney Disease. https:\/\/www.cdc.gov\/diabetes\/managing\/diabetes-kidney-disease.html. Accessed 14 Aug 2023."},{"key":"917_CR2","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2022;102(5):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","DOI":"10.1016\/j.kint.2022.06.008"},{"key":"917_CR3","unstructured":"DailyMed. KERENDIA (finerenone) tablet, film-coated. https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fc726765-5d5a-4d6e-b037-b847bda9fb7c. Accessed 14 Aug 2023."},{"issue":"3","key":"917_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1093\/AJH\/HPAC124","volume":"36","author":"PI Georgianos","year":"2023","unstructured":"Georgianos PI, Agarwal R. The nonsteroidal mineralocorticoid-receptor-antagonist finerenone in cardiorenal medicine: a state-of-the-art review of the literature. Am J Hypertens. 2023;36(3):135\u201343. https:\/\/doi.org\/10.1093\/AJH\/HPAC124.","journal-title":"Am J Hypertens"},{"issue":"1","key":"917_CR5","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3803\/EnM.2022.1629","volume":"38","author":"DL Kim","year":"2023","unstructured":"Kim DL, Lee SE, Kim NH. Renal protection of mineralocorticoid receptor antagonist, finerenone, diabetic kidney disease. Endocrinol Metab. 2023;38(1):43\u201355. https:\/\/doi.org\/10.3803\/EnM.2022.1629.","journal-title":"Endocrinol Metab"},{"issue":"24","key":"917_CR6","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/nejmoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R, et\u00a0al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021;385(24):2252\u201363. https:\/\/doi.org\/10.1056\/nejmoa2110956.","journal-title":"N Engl J Med"},{"issue":"23","key":"917_CR7","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/nejmoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD, et\u00a0al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020;383(23):2219\u201329. https:\/\/doi.org\/10.1056\/nejmoa2025845.","journal-title":"N Engl J Med"},{"key":"917_CR8","unstructured":"European Medicines Agency. Assessment report Kerendia (finerenone), EMA\/78746\/2022. www.ema.europa.eu\/en\/documents\/assessment-report\/kerendia-epar-public-assessment-report_en.pdf. 2021. Accessed 12 June 2023."},{"key":"917_CR9","unstructured":"US Food and Drug Administration. Integrated review Kerendia (finerenone). www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2021\/215341Orig1s000IntegratedR.pdf. 2021. Accessed 12 June 2023."},{"issue":"2","key":"917_CR10","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/fcp.12170","volume":"30","author":"S Lentini","year":"2016","unstructured":"Lentini S, Heinig R, Kimmeskamp-Kirschbaum N, Wensing G. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone\u2014results from first-in-man and relative bioavailability studies. Fundam Clin Pharmacol. 2016;30(2):172\u201384. https:\/\/doi.org\/10.1111\/fcp.12170.","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"917_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s13318-018-0483-9","volume":"43","author":"R Heinig","year":"2018","unstructured":"Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the novel, selective, non-steroidal mineralocorticoid receptor antagonist finerenone in healthy volunteers: results from an absolute bioavailability study and drug-drug interaction studies in vitro and in vivo. Eur J Drug Metab Pharmacokinet. 2018;43(6):715\u201327. https:\/\/doi.org\/10.1007\/s13318-018-0483-9.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"11","key":"917_CR12","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1124\/dmd.118.083337","volume":"46","author":"M Gerisch","year":"2018","unstructured":"Gerisch M, Heinig R, Engelen A, et\u00a0al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivo and in vitro. Drug Metab Dispos. 2018;46(11):1546\u201355. https:\/\/doi.org\/10.1124\/dmd.118.083337.","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"917_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/psp4.12746","volume":"11","author":"T Wendl","year":"2022","unstructured":"Wendl T, Frechen S, Gerisch M, Heinig R, Eissing T. Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone. CPT Pharmacometr Syst Pharmacol. 2022;11(2):199\u2013211. https:\/\/doi.org\/10.1002\/psp4.12746.","journal-title":"CPT Pharmacometr Syst Pharmacol"},{"issue":"6","key":"917_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/edm2.360","volume":"5","author":"C Wanner","year":"2022","unstructured":"Wanner C, Fioretto P, Kovesdy CP, et\u00a0al. Potassium management with finerenone: practical aspects. Endocrinol Diabetes Metab. 2022;5(6):1\u20138. https:\/\/doi.org\/10.1002\/edm2.360.","journal-title":"Endocrinol Diabetes Metab"},{"issue":"3","key":"917_CR15","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jdi.13183","volume":"11","author":"M Lao","year":"2020","unstructured":"Lao M, Li C, Li J, Chen D, Ding M, Gong Y. Opportunistic invasive fungal disease in patients with type 2 diabetes mellitus from Southern China: clinical features and associated factors. J Diabetes Investig. 2020;11(3):731\u201344. https:\/\/doi.org\/10.1111\/jdi.13183.","journal-title":"J Diabetes Investig."},{"issue":"5","key":"917_CR16","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1111\/j.1464-5491.2005.01701.x","volume":"23","author":"NS Soysa","year":"2006","unstructured":"Soysa NS, Samaranayake LP, Ellepola ANB. Diabetes mellitus as a contributory factor in oral candidosis. Diabet Med. 2006;23(5):455\u20139. https:\/\/doi.org\/10.1111\/j.1464-5491.2005.01701.x.","journal-title":"Diabet Med"},{"issue":"9733","key":"917_CR17","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Kondapally Seshasai SR, et\u00a0al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet (London, England). 2010;375(9733):2215\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(10)60484-9.","journal-title":"Lancet (London, England)."},{"key":"917_CR18","doi-asserted-by":"publisher","unstructured":"Wright C, Caunca M. Diabetes and hypertension. Neurovascular Neuropsychol Second Ed. Published online 2020:283-302. https:\/\/doi.org\/10.1007\/978-3-030-49586-2_13","DOI":"10.1007\/978-3-030-49586-2_13"},{"issue":"3","key":"917_CR19","doi-asserted-by":"publisher","first-page":"513","DOI":"10.2337\/dc17-2131","volume":"41","author":"IM Carey","year":"2018","unstructured":"Carey IM, Critchley JA, Dewilde S, Harris T, Hosking FJ, Cook DG. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care. 2018;41(3):513\u201321. https:\/\/doi.org\/10.2337\/dc17-2131.","journal-title":"Diabetes Care"},{"issue":"1","key":"917_CR20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.3390\/biologics3010004","volume":"3","author":"A Khanam","year":"2023","unstructured":"Khanam A, Hithamani G, Naveen J, Pradeep SR, Barman S, Srinivasan K. Management of invasive infections in diabetes mellitus: a comprehensive review. Biologics. 2023;3(1):40\u201371. https:\/\/doi.org\/10.3390\/biologics3010004.","journal-title":"Biologics"},{"issue":"4","key":"917_CR21","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/civ933","volume":"62","author":"PG Pappas","year":"2015","unstructured":"Pappas PG, Kauffman CA, Andes DR, et\u00a0al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2015;62(4):e1\u201350. https:\/\/doi.org\/10.1093\/cid\/civ933.","journal-title":"Clin Infect Dis"},{"issue":"33","key":"917_CR22","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/EURHEARTJ\/EHY339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, et\u00a0al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). Eur Heart J. 2018;39(33):3021\u2013104. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHY339.","journal-title":"Eur Heart J"},{"issue":"10","key":"917_CR23","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1007\/s40262-014-0167-9","volume":"53","author":"KB Larson","year":"2014","unstructured":"Larson KB, Wang K, Delille C, Otofokun I, Acosta EP. Pharmacokinetic enhancers in HIV therapeutics. Clin Pharmacokinet. 2014;53(10):865\u201372. https:\/\/doi.org\/10.1007\/s40262-014-0167-9.","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"917_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1080\/10428194.2022.2150820","volume":"64","author":"B Tariq","year":"2023","unstructured":"Tariq B, Ou YC, Stern JC, et\u00a0al. A phase 1, open-label, randomized drug\u2013drug interaction study of zanubrutinib with moderate or strong CYP3A inhibitors in patients with B-cell malignancies. Leuk Lymphoma. 2023;64(2):329\u201338. https:\/\/doi.org\/10.1080\/10428194.2022.2150820.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"917_CR25","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s13318-019-00581-9","volume":"45","author":"I Poggesi","year":"2020","unstructured":"Poggesi I, Li LY, Jiao J, et\u00a0al. Effect of fluconazole and itraconazole on the pharmacokinetics of erdafitinib in healthy adults: a randomized, open-label, drug-drug interaction study. Eur J Drug Metab Pharmacokinet. 2020;45(1):101\u201311. https:\/\/doi.org\/10.1007\/s13318-019-00581-9.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"4","key":"917_CR26","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1007\/s00280-019-03907-1","volume":"84","author":"V Aslanis","year":"2019","unstructured":"Aslanis V, Umehara K, Huth F, et\u00a0al. Multiple administrations of fluconazole increase plasma exposure to ruxolitinib in healthy adult subjects. Cancer Chemother Pharmacol. 2019;84(4):749\u201357. https:\/\/doi.org\/10.1007\/s00280-019-03907-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"917_CR27","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s00228-018-2559-5","volume":"75","author":"ML Boof","year":"2019","unstructured":"Boof ML, Alatrach A, Ufer M, Dingemanse J. Interaction potential of the dual orexin receptor antagonist ACT-541468 with CYP3A4 and food: results from two interaction studies. Eur J Clin Pharmacol. 2019;75(2):195\u2013205. https:\/\/doi.org\/10.1007\/s00228-018-2559-5.","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"917_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/cpt.2603","volume":"112","author":"RSP Singh","year":"2022","unstructured":"Singh RSP, Toussi SS, Hackman F, et\u00a0al. Innovative randomized phase i study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of nirmatrelvir. Clin Pharmacol Ther. 2022;112(1):101\u201311. https:\/\/doi.org\/10.1002\/cpt.2603.","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"917_CR29","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1365-2125.2009.03545.x","volume":"68","author":"DJ Greenblatt","year":"2009","unstructured":"Greenblatt DJ, Peters DE, Oleson LE, et\u00a0al. Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase. Br J Clin Pharmacol. 2009;68(6):920\u20137. https:\/\/doi.org\/10.1111\/j.1365-2125.2009.03545.x.","journal-title":"Br J Clin Pharmacol"},{"key":"917_CR30","doi-asserted-by":"publisher","unstructured":"Black P, Ward LI. http:\/\/www.cdc.gov\/pcd\/issues\/2020\/20_0130.htm Preventing Chronic disease. Prevalence of multiple chronic conditions among US adults, 2018. Prev Chronic Dis. 2018;17. https:\/\/doi.org\/10.5888\/pcd17.200130","DOI":"10.5888\/pcd17.200130"},{"issue":"8","key":"917_CR31","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1093\/GERONA\/GLV013","volume":"70","author":"CJ Charlesworth","year":"2015","unstructured":"Charlesworth CJ, Smit E, Lee DSH, Alramadhan F, Odden MC. Polypharmacy among adults aged 65 years and older in the United States: 1988\u20132010. J Gerontol A Biol Sci Med Sci. 2015;70(8):989\u201395. https:\/\/doi.org\/10.1093\/GERONA\/GLV013.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"issue":"4","key":"917_CR32","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0027-9684(15)31280-3","volume":"100","author":"R Hazin","year":"2008","unstructured":"Hazin R, Abuzetun JY, Suker M, Porter J. Rhabdomyolysis induced by simvastatin-fluconazole combination. J Natl Med Assoc. 2008;100(4):444\u20136. https:\/\/doi.org\/10.1016\/S0027-9684(15)31280-3.","journal-title":"J Natl Med Assoc"},{"key":"917_CR33","doi-asserted-by":"publisher","DOI":"10.3389\/FCVM.2023.984572","author":"Y Yuan","year":"2023","unstructured":"Yuan Y, Wang C, Yao H. A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole. Front Cardiovasc Med. 2023. https:\/\/doi.org\/10.3389\/FCVM.2023.984572.","journal-title":"Front Cardiovasc Med."},{"key":"917_CR34","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.22CR03288","author":"O Alli-Balogun","year":"2023","unstructured":"Alli-Balogun O, Bidkhanian P, Singh G, Korenis P. Clozapine toxicity from drug-drug interaction when given with fluoxetine and diltiazem. Prim care companion. CNS Disord. 2023. https:\/\/doi.org\/10.4088\/PCC.22CR03288.","journal-title":"CNS Disord."},{"issue":"6","key":"917_CR35","doi-asserted-by":"publisher","first-page":"648.e9","DOI":"10.1016\/J.GENHOSPPSYCH.2010.08.003","volume":"32","author":"TT Levin","year":"2010","unstructured":"Levin TT, Bakr MH, Nikolova T. Case report: delirium due to a diltiazem-fentanyl CYP3A4 drug interaction. Gen Hosp Psychiatry. 2010;32(6):648.e9-648.e10. https:\/\/doi.org\/10.1016\/J.GENHOSPPSYCH.2010.08.003.","journal-title":"Gen Hosp Psychiatry"},{"issue":"8","key":"917_CR36","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1177\/10600280221143131","volume":"57","author":"MS Rauser","year":"2023","unstructured":"Rauser MS, McGrane IR. A CYP3A4 drug-drug interaction between nirmatrelvir\/ritonavir and nifedipine leading to edema, oliguria, and acute kidney injury: a case report. Ann Pharmacother. 2023;57(8):991\u20132. https:\/\/doi.org\/10.1177\/10600280221143131.","journal-title":"Ann Pharmacother"},{"issue":"10","key":"917_CR37","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0006-2952(99)00026-X","volume":"57","author":"J Drewe","year":"1999","unstructured":"Drewe J, Gutmann H, Fricker G, T\u00f6r\u00f6k M, Beglinger C, Huwyler J. HIV protease inhibitor ritonavir: a more potent inhibitor of P-glycoprotein than the cyclosporine analog SDZ PSC 833. Biochem Pharmacol. 1999;57(10):1147\u201352. https:\/\/doi.org\/10.1016\/S0006-2952(99)00026-X.","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"917_CR38","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/0976-0105.177703","volume":"7","author":"A Nair","year":"2016","unstructured":"Nair A, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27. https:\/\/doi.org\/10.4103\/0976-0105.177703.","journal-title":"J Basic Clin Pharm."},{"key":"917_CR39","unstructured":"Electronic Medicines Compendium (EMC). Diflucan 200 mg hard capsules\u2014summary of product characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/5981\/smpc. Accessed 8 Nov 2023"},{"key":"917_CR40","unstructured":"Electronic Medicines Compendium (EMC). Viazem XL 120\u00a0mg\u2014summary of product characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/product\/15\/smpc. Accessed 8 Nov 2023"},{"key":"917_CR41","unstructured":"Electronic Medicines Compendium (EMC). Norvir 100 mg film-coated tablets\u2014summary of product characteristics (SmPC). https:\/\/www.medicines.org.uk\/emc\/search?q=ritonavir. Accessed 8 Nov 2023"},{"issue":"3","key":"917_CR42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/pharmaceutics11030133","volume":"11","author":"M Kim","year":"2019","unstructured":"Kim M, Son H, Noh K, Kim E, Shin BS, Kang W. Effects of verapamil and diltiazem on the pharmacokinetics and pharmacodynamics of rivaroxaban. Pharmaceutics. 2019;11(3):1\u201310. https:\/\/doi.org\/10.3390\/pharmaceutics11030133.","journal-title":"Pharmaceutics"},{"key":"917_CR43","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/J.EJPB.2016.11.034","volume":"112","author":"AY Abuhelwa","year":"2017","unstructured":"Abuhelwa AY, Williams DB, Upton RN, Foster DJR. Food, gastrointestinal pH, and models of oral drug absorption. Eur J Pharm Biopharm. 2017;112:234\u201348. https:\/\/doi.org\/10.1016\/J.EJPB.2016.11.034.","journal-title":"Eur J Pharm Biopharm"},{"issue":"11","key":"917_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/PHARMACEUTICS12111040","volume":"12","author":"LT Ngo","year":"2020","unstructured":"Ngo LT, Yang SY, Tran QT, Kim SK, Yun HY, Chae JW. Effects of carbamazepine and phenytoin on pharmacokinetics and pharmacodynamics of rivaroxaban. Pharmaceutics. 2020;12(11):1\u201316. https:\/\/doi.org\/10.3390\/PHARMACEUTICS12111040.","journal-title":"Pharmaceutics"},{"issue":"2","key":"917_CR45","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/J.XPHS.2021.09.029","volume":"111","author":"D Damoiseaux","year":"2022","unstructured":"Damoiseaux D, Li W, Beijnen JH, Schinkel AH, Huitema ADR, Dorlo TPC. Population pharmacokinetic modelling to support the evaluation of preclinical pharmacokinetic experiments with lorlatinib. J Pharm Sci. 2022;111(2):495\u2013504. https:\/\/doi.org\/10.1016\/J.XPHS.2021.09.029.","journal-title":"J Pharm Sci"},{"issue":"9","key":"917_CR46","doi-asserted-by":"publisher","first-page":"3550","DOI":"10.1111\/BCP.14771","volume":"87","author":"NA Kratochwil","year":"2021","unstructured":"Kratochwil NA, Stillhart C, Diack C, Nagel S, Al Kotbi N, Frey N. Population pharmacokinetic analysis of RO5459072, a low water-soluble drug exhibiting complex food-drug interactions. Br J Clin Pharmacol. 2021;87(9):3550\u201360. https:\/\/doi.org\/10.1111\/BCP.14771.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"917_CR47","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ, et\u00a0al. Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet. 2020;59(3):359\u201370. https:\/\/doi.org\/10.1007\/s40262-019-00820-x.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"917_CR48","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40262-021-01083-1","volume":"61","author":"SC Goulooze","year":"2022","unstructured":"Goulooze SC, Snelder N, Seelmann A, et\u00a0al. Finerenone dose\u2013exposure\u2013serum potassium response analysis of FIDELIO-DKD phase III: the role of dosing, titration, and inclusion criteria. Clin Pharmacokinet. 2022;61(3):451\u201362. https:\/\/doi.org\/10.1007\/s40262-021-01083-1.","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"917_CR49","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1517\/17425255.2.6.875","volume":"2","author":"M Martignoni","year":"2006","unstructured":"Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2006;2(6):875\u201394. https:\/\/doi.org\/10.1517\/17425255.2.6.875.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-024-00917-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-024-00917-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T13:10:53Z","timestamp":1731071453000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-024-00917-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1007\/s13318-024-00917-0","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"28 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was supported by Chungnam National University, Institute of Information & communications Technology Planning Evaluation (IITP) grant funded by the Korean government (MSIT) [no. RS-2022-00155857, Artificial Intelligence Convergence Innovation Human Resources Development (Chungnam National University)] and National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT; no. RS-2023-00278597, NRF-2022R1A2C1010929, NRF2022R1A5A7085156), and the Korea Environmental Industry Technology Institute (KEITI) through Core Technology Development Project for Environmental Diseases Prevention and Management (2021003310001), funded by the Korean Ministry of Environment (MOE).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors have no conflict of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets generated and analyzed during the current study are available from the corresponding author upon reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"Animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of Chungnam National University (approval no. 202304A-CNU-064) on 26 April 2023.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The codes generated during the current study are available from the corresponding author upon reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors participated in the research design. Animal experiments were performed by T.T.B., S.H.K., J.W.J., Q.T.T., S.Y.Y., H.J.L., and S.W.P. Data analysis was conducted by T.T.B., S.H.K., and J.W.J. The draft of the manuscript was written by T.T.B., S.H.K., J.W.J., L.N.T., H.Y.Y., and J.W.C. All authors approved the final version of the manuscript for publication.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}